Glycemic Control in Diabetes in Three Danish Counties

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 12, 2005, Pages 1366-1372

  Jørgensen, Lone G M ^a   Lund, Erik D ^a   Brandslund, Ivan ^a,i   Petersen, Per Hyltoft ^b   Heickendorff, Lene ^c   Christensen, Niels J ^c   Møller, Holger Jon ^c   Hansen, Erik Kjærsgaard ^c   Hendel, Jørn ^d   Christensen, Cramer ^a   Schmitz, Anita ^a   Reinholdt, Birgitte ^e   Hastrup, Jens ^f   Skjødt, Hanne ^g   Eriksen, Ebbe Wendel ^h  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

^e Fredericia Sygehus   (Denmark)

^f KOLDING HOSPITAL   (Denmark)

^g HORSENS REGIONAL HOSPITAL   (Denmark)

^h General Practice Office   (Denmark)

ⁱ UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

clinical outcome; glycated hemoglobin A1c (HbA1c; hyperglycemia; prognosis; treatment efficacy

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DENMARK; DIABETES MELLITUS; FEMALE; HUMAN; HYPERGLYCEMIA; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROBABILITY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DENMARK; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; PROBABILITY; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644877700     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2005.233     Document Type: Article

References (37)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complication trial. Diabetes 1995; 44: 969-983.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. Khaw K.-T., Wareham N, Lubin R, Bingham S, Oakes S, Welch A, et al. Glucated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-8.
5. Stratton IM, Adler A, Neil HAW, Matthews D, Manley SE, Cull CA, et al. Association of glycaemia with macrovas-cular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000; 321: 405-412.
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Research Clinical Practice 1995; 28: 103-117.
7. Jeffcoate SL. Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabetic Med 2004; 21: 657-665.
8. American Diabetes Association. Position statements & ADA statements. Diabetes Care 2005; 28: 69-71.
9. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes. Diabet Med 1999; 16: 716-730.
10. Clark CM, How should we respond to the worldwide diabetes epidemic? Diabetes Care 1998; 21: 475-476.
11. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-524.
12. Borch-Johnsen K. Prevention of a public disease and its consequences. Ugeskr Laeger 2004; 166: 1316-1320.
13. McCance DR, Hanson RL, Pettitt DJ, Bennett PH, Hadden DR, Knowler WC. Diagnosing diabetes mellitus-do we need new criteria?. Diabetologia 1997; 40: 247-255.
14. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000; 23: 176-180.
15. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al., for The Finnish Diabetes Prevention Study Group. N Engl J Med 2001; 344: 1343-1350.
16. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 2001; 286: 1195-200.
17. Gregg EW, Cadwell BL, Cheng YJ, Cowie CC, Williams DE, Geiss L, et al. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US. Diabetes Care 2004; 27: 2806-2812.
18. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28: S4-S36.
19. The Danish Diabetes Association. Diabetesbehandling i Danmarkmal og midler, 2005 (http://www.diabetes.dk).
20. Jprgensen LG, Brandslund I, Stahl M, Hyltoft Petersen P, Iversen S, Klitgaard N, et al. Upper reference limit, analytical quality specifications and clinical use of haemoglobin A1c. Scand J Clin Lab Invest 2002; 62: 609-622.
21. Schellhase KG, Koepsell TD, Weiss NS. Glycemic control and the risk of multiple microvascular diabetic complications. Fam Med 2005; 37: 125-130.
22. Gale EA. Is there really an epidemic of type 2 diabetes. Lancet 2003; 362: 503-504.
23. Danish Statistics. Population statistics for Danish Counties, 2005 (http://www.dst.dk/).
24. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Haemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005; 51: 753-758.
25. Hyltoft Petersen P, Blaabjerg O, Andersen M, Jorgensen LG, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004; 42: 715-724.
26. Diem K, editor. Documenta Geigy. Scientific Tables, 6th ed. Ardsley, NY: Geigy Pharmaceuticals, 1962.
27. Campbell MJ, Gardiner MJ. Calculating confidence intervals for some non-parametric analyses. In: Gardiner MJ, Altman DG, editors. Statistics with confidence, 6th ed. London, UK: Br Med J, 1994: 71-79.
28. Jørgensen LG, Hyltoft Petersen P, Brandslund I. The impact of variability in the risk of disease exemplified by diagnosing diabetes mellitus based on ADA and WHO criteria as gold standard. Int J Risk Assess Manage 2005; 5: 358-373.
29. Hyltoft Petersen P, Brandslund I, Jørgensen L, Stahl M, de Fine Olivarius N, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glucose as the basis for analytical quality specifications in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus III. Scand J Clin Lab Invest 2001; 61: 191-204.
30. Jørgensen LG, Brandslund I, Hyltoft Petersen P, de Fine Olivarius N, Stahl M. The effect of the new ADA and WHO guidelines on the number of diagnosed diabetes mellitus cases. Clin Chem Lab Med 2003; 41: 1246-1250.
31. de Bievre P. Target measurement uncertainty II: are they coming? Accred Qual Assur 2004; 9: 651-652.
32. Henny J, Hyltoft Petersen P. Reference values: from philosophy to a tool for laboratory medicine. Clin Chem Lab Med 2004; 42: 686.
33. Ritchie RF, Palomaki G. Selecting relevant populations for reference intervals. Clin Chem Lab Med 2004; 42: 702-709.
34. Jørgensen LG, Brandslund I, Hyltoft Petersen P. Should we maintain the 95 percent reference intervals in the era of wellness testing. A concept paper. Clin Chem Lab Med 2004; 42: 747-751.
35. Klee GG. Clinical interpretation of reference intervals and reference limits. A plea for assay harmonization. Clin Chem Lab Med 2004; 42: 752-757.
36. Jprgensen LG, Löber J, Carlsen NLT, Momsen G, Hirsch F. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta 1996; 249: 77-91.
37. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986; 8476: 307-310.